Raimund Strehl

Raimund Strehl has worked in the biotech and regenerative medicine industry since 2003. In that year, they took on the role of CTO at Cellartis AB, where they were overall responsible for departments product development and manufacturing of human pluripotent stem cell derived products, as well as the laboratories and IT infrastructure. Raimund was also a key contact in a major collaboration with Novo Nordisk to develop insulin producing beta-cells from human pluripotent stem cells for therapeutic applications in diabetes treatment. In 2013, they became the Owner/Director of Consulting in Biotech and Regenerative Medicine. In 2015, they took on the role of CTO at NovaHep AB. In 2017, they became CTO at VERIGRAFT.

Raimund Strehl obtained a Masters degree in Biology from the University of Regensburg in 1996 and a PhD Degree in Cell Biology from the same university in 2000, with a field of study in Cell/Cellular Biology and Histology.